Clinical trial
A Multi-center, Open-label, Randomized, Phase II Trial of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel as First-line Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT07040644 is registered in ClinicalTrials.gov with Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Open-label, Randomized, Phase II Trial of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel as First-line Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- September 30, 2025
- Completion date
- June 30, 2028
- Enrollment
- 150 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.